MygoGenesis

Executive Summary

MygoGenesis is a private cellular medicine company based in San Diego, founded in 2018. The company has developed a proprietary process called Mygotic™ that converts somatic cells into totipotent cells, which can then differentiate into nearly any cell or tissue type. This approach aims to overcome challenges associated with alternative cell reprogramming methods, such as induced pluripotent stem cells or direct differentiation. MygoGenesis is exploring applications in therapeutics, regenerative medicine, and food/water testing. The company has not disclosed total funding, valuation, or specific pipeline programs, and no clinical trials are publicly listed. As a private entity, it relies on strategic partnerships and financing to advance its technology platform.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Funding Round60% success
• Q4 2026Strategic Partnership or Licensing Deal with a Major Pharma40% success
• Q1 2027Preclinical Proof-of-Concept Data Release for a Lead Indication50% success